Prevalence, management, and new treatment modalities of EBV-DNA-emia and EBV-PTLD after allo-HCT : survey of Infectious Diseases Working Party EBMT
© 2023. The Author(s), under exclusive licence to Springer Nature Limited..
The aim of this study was to determine the current approach of EBV-driven post-transplant complications in context of monitoring, diagnosis, prevalence and treatment in EBMT transplant centers. Routine serology testing in patient and donor before HCT is performed in 95.5% centers. Pretransplant EBV-DNA is routinely tested in all patients in 32.7% centers. Monitoring for EBV infection is feasible in 98.2% centers: including 66.7% centers using standardized PCR. Post-HCT regular monitoring is performed in all patients in 80.5% centers. Anti-EBV prophylaxis with rituximab is used in 12.4% centers. Frequency of csEBV-DNA-emia was 7.4% (adults: 6.2%, children: 12.6%). The PCR threshold used to start preemptive treatment was differentiated among centers. Frequency of EBV-PTLD was 1.6% (adults: 1.3%; children: 3.5%). First-line therapy of EBV-driven complications was rituximab and reduction of immunosuppressive therapy. The rate of failure of first-line preemptive treatment was 12.0%. EBV-specific viral-specific T-lymphocytes were available in 46.0% centers. A number of new experimental therapies were given in 28 patients with resistant/refractory PTLD. In conclusion, the prevalence of EBV-DNA-emia and EBV-PTLD over the period 2020-2021 decreased in comparison to historical data. New trends (routine pretransplant screening for EBV-DNA, wider access to VST, new experimental therapies) are being observed in management of EBV infection after allo-HCT.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:59 |
|---|---|
| Enthalten in: |
Bone marrow transplantation - 59(2024), 1 vom: 14. Jan., Seite 59-65 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Styczynski, Jan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 12.01.2024 Date Revised 04.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41409-023-02129-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363645861 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363645861 | ||
| 003 | DE-627 | ||
| 005 | 20240305232012.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41409-023-02129-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1317.xml |
| 035 | |a (DE-627)NLM363645861 | ||
| 035 | |a (NLM)37872300 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Styczynski, Jan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prevalence, management, and new treatment modalities of EBV-DNA-emia and EBV-PTLD after allo-HCT |b survey of Infectious Diseases Working Party EBMT |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.01.2024 | ||
| 500 | |a Date Revised 04.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Nature Limited. | ||
| 520 | |a The aim of this study was to determine the current approach of EBV-driven post-transplant complications in context of monitoring, diagnosis, prevalence and treatment in EBMT transplant centers. Routine serology testing in patient and donor before HCT is performed in 95.5% centers. Pretransplant EBV-DNA is routinely tested in all patients in 32.7% centers. Monitoring for EBV infection is feasible in 98.2% centers: including 66.7% centers using standardized PCR. Post-HCT regular monitoring is performed in all patients in 80.5% centers. Anti-EBV prophylaxis with rituximab is used in 12.4% centers. Frequency of csEBV-DNA-emia was 7.4% (adults: 6.2%, children: 12.6%). The PCR threshold used to start preemptive treatment was differentiated among centers. Frequency of EBV-PTLD was 1.6% (adults: 1.3%; children: 3.5%). First-line therapy of EBV-driven complications was rituximab and reduction of immunosuppressive therapy. The rate of failure of first-line preemptive treatment was 12.0%. EBV-specific viral-specific T-lymphocytes were available in 46.0% centers. A number of new experimental therapies were given in 28 patients with resistant/refractory PTLD. In conclusion, the prevalence of EBV-DNA-emia and EBV-PTLD over the period 2020-2021 decreased in comparison to historical data. New trends (routine pretransplant screening for EBV-DNA, wider access to VST, new experimental therapies) are being observed in management of EBV infection after allo-HCT | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 650 | 7 | |a DNA, Viral |2 NLM | |
| 700 | 1 | |a Tridello, Gloria |e verfasserin |4 aut | |
| 700 | 1 | |a Wendel, Lotus |e verfasserin |4 aut | |
| 700 | 1 | |a Knelange, Nina |e verfasserin |4 aut | |
| 700 | 1 | |a Cesaro, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Gil, Lidia |e verfasserin |4 aut | |
| 700 | 1 | |a Ljungman, Per |e verfasserin |4 aut | |
| 700 | 1 | |a Mikulska, Malgorzata |e verfasserin |4 aut | |
| 700 | 1 | |a Averbuch, Dina |e verfasserin |4 aut | |
| 700 | 1 | |a de la Camara, Rafael |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bone marrow transplantation |d 1986 |g 59(2024), 1 vom: 14. Jan., Seite 59-65 |w (DE-627)NLM012638250 |x 1476-5365 |7 nnns |
| 773 | 1 | 8 | |g volume:59 |g year:2024 |g number:1 |g day:14 |g month:01 |g pages:59-65 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41409-023-02129-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 59 |j 2024 |e 1 |b 14 |c 01 |h 59-65 | ||